She previously served on Gilead's scientific advisory board from 1989 to 2007.
Barton is the John G. Kirkwood and Arthur A. Noyes Professor of Chemistry and Norman Davidson Leadership chair of the Division of Chemistry and Chemical Engineering at the California Institute of Technology, where she has been a faculty member for nearly 30 years.
She served on the board of directors of the Dow Chemical company from 1993 to 2017, and currently is a member of the Materials Science Advisory Committee of DowDuPont, Inc. She founded and served on the board of GeneOhm Sciences, Inc., a molecular diagnostic company acquired by Becton Dickinson and company.
She is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society. In 2011, Barton received the National Medal of Science for her discovery of new chemistry of the DNA helix.
Gilead Sciences discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 40 countries worldwide.
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits